Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes Anick Bérard, MSc, PhD, Odile Sheehy, MSc, Marie-Laure Kurzinger, MSc, Juhaeri Juhaeri, PhD Journal of Allergy and Clinical Immunology Volume 138, Issue 1, Pages 97-104.e7 (July 2016) DOI: 10.1016/j.jaci.2016.01.021 Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig E1 Study population selection. INCS, Intranasal corticosteroids; MCM, major congenital malformation. Journal of Allergy and Clinical Immunology 2016 138, 97-104.e7DOI: (10.1016/j.jaci.2016.01.021) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig E2 Prevalence of major congenital malformation, respiratory system malformations, and pregnancies exposed to triamcinolone or other intranasal corticosteroids per year of conception. Journal of Allergy and Clinical Immunology 2016 138, 97-104.e7DOI: (10.1016/j.jaci.2016.01.021) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions